Hypoxia Pathways for Early Recovery After Spinal Cord Injury

NCT ID: NCT07002437

Last Updated: 2025-12-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-20

Study Completion Date

2027-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spinal cord injury (SCI) disrupts neural pathways to respiratory motor neurons, diminishing breathing capacity and airway defense (e.g., cough). Indeed, respiratory impairment is a leading cause of infection, re-hospitalization and death after SCI. There is a critical need for new strategies to restore breathing ability and airway defense in people with SCI. Acute intermittent hypoxia (AIH) - repetitive exposure to brief episodes of low inspired oxygen - is a promising strategy to restore breathing capacity by promoting spinal neuroplasticity. Exciting outcomes in \>12 SCI trials completed to date demonstrate that AIH improves human respiratory and limb function. Unfortunately, \~40% of individuals exhibit minimal response to AIH, making it essential to 1) optimize AIH protocols to maximize functional benefits; and 2) identify genetic biomarkers distinguishing those most/least likely to benefit from AIH-based treatments.

The purpose of the pilot study, to be conducted in a small sample of participants with sub-acute SCI (2 weeks to 6 months post injury), is to preliminarily compare the effects of two intermittent hypoxia protocols. Since AIH-induced plasticity may be induced via serotonin or adenosine-driven mechanisms and these pathways compete and inhibit each other, each protocol favors a distinct mechanistic pathway. Our long-term objective is to test the hypothesis that a longer duration (i.e., augmented) hypoxia protocol, favoring adenosine mechanisms, enhances respiratory motor plasticity more than an AIH protocol targeting serotonin mechanisms (low O2 + CO2) in people with sub-acute SCI. Since an individual's genetics can influence the response to rehabilitation, we are also investigating how certain genes are related to breathing changes after these treatments.

Data acquired through this pilot study will be used to inform a larger, more definitive clinical trial and will contribute to estimations of the magnitude and direction of effects.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The specific focus of this pilot study is to obtain preliminary data to inform a larger, more definitive clinical trial. The long-term objective of this line of work is to test the hypothesis that an acute intermittent hypoxia protocol (3, 5 min episodes, 9-13% FiO2; augmented AIH (aAIH)) favoring adenosine mechanisms, enhances respiratory motor plasticity more than an AIH protocol targeting serotonin mechanisms (1 min 9% FiO2 + CO2) in people with sub-acute SCI. Since an individual's genetics can influence the response to rehabilitation, investigators are also collecting preliminary data regarding how certain genes are related to breathing changes after these treatments.

Data acquired through this pilot study will be used to estimate the magnitude and direction of effects.

This line of research will inform AIH protocol optimization to enhance the clinical effects of AIH treatments designed to improve rehabilitation outcomes.

The following Aims will be addressed:

Aim 1: To preliminarily test the hypothesis that augmented acute intermittent hypoxia (aAIH) is a more potent stimulus to induce respiratory motor plasticity than AIHH (low oxygen with hypercapnia) in people with sub-acute SCI.

The investigators predict that 6 sessions of aAIH (3, 5-minute episodes of 9-13% O2; 3-minute intervals) will elicit greater respiratory motor plasticity than AIHH (15, 1-minute episodes of 9-13% O2 with 4-5% CO2; 1.5-minute intervals) or Sham (5, 3-minute episodes of 21% O2) in individuals with SCI, 2 weeks to 6 months post injury.

The primary outcomes include maximum pressure generation and cough function 1-day and 1-week post-intervention. Secondary, exploratory outcomes will be biceps (elbow flexion) force output.

Aim 2: To obtain preliminary data regarding the association between dysfunctional genetic variants, linked with molecules necessary for AIH-induced respiratory motor plasticity, and the magnitude of response (change in primary outcomes) in response to aAIH or AIHH in individuals with sub-acute SCI.

The investigators predict that individuals with dysfunctional single nucleotide polymorphisms (SNPs) associated with pro-plasticity genes have blunted responses to aAIH and/or AIHH treatments.

* Augmented Acute intermittent hypoxia (aAIH): This intervention will involve breathing low-oxygen air through a facemask that covers the nose and mouth. Participants will be asked to breathe the low-oxygen air for 3 periods (about 5 minutes each period). A mask will be secured and adjusted to the face and the participant will be able to breathe naturally and normally. Between the \~ 5 minute periods of lower oxygen, the participant will breathe higher oxygen levels that are 'normal' or consistent with room air for about 3 minutes. Heart rate, blood oxygen saturation, and blood pressure will be monitored. The gas mixture will be adjusted if a participant's blood oxygen saturation drops below 80%.
* Acute intermittent hypercapnic hypoxia, lower oxygen with CO2 (AIHH): This intervention delivery using the facemask will be identical to the aAIH described above, except that lower oxygen will be combined with higher carbon dioxide air. For this intervention, the participant will be asked to breathe the low oxygen air with higher carbon dioxide air for 15 periods (\~1 minute each). Between periods of breathing this gas mixture through the facemask, the participant will breathe higher oxygen levels that are normal for \~1.5 minutes. Heart rate, blood oxygen saturation, and blood pressure will be monitored. The gas mixture will be adjusted if a participant's blood oxygen saturation drops below 80%.
* Sham/Placebo: This intervention will be identical to the two procedures described above, except that normal-oxygen, normal-carbon dioxide air (same as room air) will be delivered through the facemask for 5 periods (\~3 minutes each). Heart rate, blood oxygen saturation, and blood pressure will be monitored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries (SCI)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

AIHH

Participants will complete a baseline testing session, 6 sessions of acute intermittent hypercapnic hypoxia (AIHH) intervention (15, 1-minute episodes of 9-13% O2 + 4-5% CO2, 1.5-minute intervals), and post-test assessments 1-day and 1-week after the last intervention.

Group Type EXPERIMENTAL

Acute Intermittent Hypercapnic-Hypoxia (AIHH)

Intervention Type OTHER

AIHH consists of 1-min episodes of low oxygen (9% O2) and elevated carbon dioxide (5% CO2), interspersed with 1.5 min room air.

Each participant will complete 6 sessions of AIHH exposure, which consists of 15, 1-minute hypercapnic hypoxic episodes (4-5% inspired CO2, 9-13% inspired O2), with 1.5-minute intervals of room air breathing (21% O2). Gas mixtures will be delivered in the same manner described for AIH intervention. Participant safety will be continuously monitored in real-time using LabChart software. For instance, inspired and expired concentrations of CO2 and O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, heart rate, and blood pressure) will be monitored.

aAIH

Participants will complete a baseline testing session, 6 sessions of augmented acute intermittent hypoxia (aAIH) intervention (3, 5-minute episodes of 9-13% O2, 3-minute intervals), and post-test assessments 1-day and 1-week after the last intervention.

Group Type EXPERIMENTAL

Augmented Acute Intermittent Hypoxia (aAIH)

Intervention Type OTHER

aAIH (augmented acute intermittent hypoxia) consists of 3, 5-minute episodes of low oxygen (9-13% O2), interspersed with 3-min room air intervals.

Each study participant will complete 6 sessions of augmented AIH (aAIH), which consists of 3, 5-minute exposures. Each exposure involves a 5-minute hypoxic episode (9-13% inspired O2), with a 3-min interval of room air breathing (21% O2). Gas mixtures will be delivered via Douglas bags (pre-filled with desired gas mixture) that are coupled to a non-rebreathing valve and facemask. A manual-control valve allows seamless gas mixture switching. Participant safety will be continuously monitored in real-time using non-invasive sensors and LabChart software. For instance, inspired and expired concentrations of O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, tidal volume, heart rate, and blood pressure) will be continuously monitored.

Sham

Participants will complete a baseline testing session, 6 sessions of sham intervention (5, 3-minute episodes of 21% O2, 2-minute intervals), and post-test assessments 1-day and 1-week after the last intervention.

Group Type SHAM_COMPARATOR

Sham AIH

Intervention Type OTHER

Six sessions of sham AIH with episodes of normal room air (21% O2).

Sham experiments will use methods identical to AIH/AIHH protocols except that normoxic gas (21% inspired O2) will be delivered. Since the timing and intervals vary with each protocol, the sham will use a distinct protocol involving 5, 3-min episodes with 2 min intervals between each episode. The valve on the non-rebreathing mask will be turned to deliver these episodes, but 21% O2 will be delivered throughout.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Augmented Acute Intermittent Hypoxia (aAIH)

aAIH (augmented acute intermittent hypoxia) consists of 3, 5-minute episodes of low oxygen (9-13% O2), interspersed with 3-min room air intervals.

Each study participant will complete 6 sessions of augmented AIH (aAIH), which consists of 3, 5-minute exposures. Each exposure involves a 5-minute hypoxic episode (9-13% inspired O2), with a 3-min interval of room air breathing (21% O2). Gas mixtures will be delivered via Douglas bags (pre-filled with desired gas mixture) that are coupled to a non-rebreathing valve and facemask. A manual-control valve allows seamless gas mixture switching. Participant safety will be continuously monitored in real-time using non-invasive sensors and LabChart software. For instance, inspired and expired concentrations of O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, tidal volume, heart rate, and blood pressure) will be continuously monitored.

Intervention Type OTHER

Acute Intermittent Hypercapnic-Hypoxia (AIHH)

AIHH consists of 1-min episodes of low oxygen (9% O2) and elevated carbon dioxide (5% CO2), interspersed with 1.5 min room air.

Each participant will complete 6 sessions of AIHH exposure, which consists of 15, 1-minute hypercapnic hypoxic episodes (4-5% inspired CO2, 9-13% inspired O2), with 1.5-minute intervals of room air breathing (21% O2). Gas mixtures will be delivered in the same manner described for AIH intervention. Participant safety will be continuously monitored in real-time using LabChart software. For instance, inspired and expired concentrations of CO2 and O2 will be monitored by continuous recordings of arterial O2 saturation and end-tidal gas, respectively. Furthermore, vital signs (respiratory rate, heart rate, and blood pressure) will be monitored.

Intervention Type OTHER

Sham AIH

Six sessions of sham AIH with episodes of normal room air (21% O2).

Sham experiments will use methods identical to AIH/AIHH protocols except that normoxic gas (21% inspired O2) will be delivered. Since the timing and intervals vary with each protocol, the sham will use a distinct protocol involving 5, 3-min episodes with 2 min intervals between each episode. The valve on the non-rebreathing mask will be turned to deliver these episodes, but 21% O2 will be delivered throughout.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adults 18-70 years of age
2. Sub-acute incomplete SCI 2 weeks to 6 months after injury, at or below C1-T6 Incomplete SCI based on residual sensory and motor function below the level of the injury or injury classification of B, C, D at initial screening according to the American Spinal Injury Association Impairment Classification and the International Standards for the Neurological Classification of SCI.

-OR- Sub-acute complete SCI 2 weeks to 6 months after injury at or below C4-T6 Complete SCI based on the absence of residual sensory or motor function below the level of injury or injury classification of A at initial screening according to the American Spinal Injury Association Impairment Classification and the International Standards for the Neurological Classification of SCI.
3. Medically stable with physician clearance
4. SCI due to non-progressive etiology

Exclusion Criteria

1. Current diagnosis of an additional neurologic condition such as Multiple Sclerosis, Parkinson disease, stroke, or brain injury
2. Severe illness or infection, including non-healing decubitus ulcers, untreated bladder or urinary tract infections, cardiovascular disease, lung disease, active heterotopic ossification, or uncontrolled hypertension
3. Severe neuropathic pain
4. Known pregnancy
5. Severe uncontrolled autonomic dysreflexia
6. Currently hospitalized in an acute care hospital
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brooks Rehabilitation

OTHER

Sponsor Role collaborator

University of Florida

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Emily J Fox, PT, DPT, MHS, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Florida & Brooks Rehabilitation

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Brooks Rehabilitation

Jacksonville, Florida, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Emily J Fox, PT, DPT, MHS, PhD

Role: CONTACT

904-742-2500

Hannah J Snyder, M.S.

Role: CONTACT

904-345-6910

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hannah J Snyder

Role: primary

904-345-6910

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB202500467

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AIH for Spinal Cord Repair
NCT03780829 RECRUITING EARLY_PHASE1
AIH-induced Walking Recovery After Subacute SCI
NCT02632422 ACTIVE_NOT_RECRUITING NA
Improving Walking After Spinal Cord Injury
NCT07223710 NOT_YET_RECRUITING PHASE1/PHASE2